FIRST ASIA-PACIFIC SALIVA SYMPOSIUM
Plenary Speakers
  • University of California, Los Angeles
    David T.W. Wong, D.M.D., D.M.Sc. is the Felix and Mildred Yip Endowed Chair in Dentistry and a Professor in the Section of Oral Biology in the Division of Oral Biology and Medicine. He is the Associate Dean of Research and the Director of the UCLA Center for Oral/Head and Neck Research. He is an active scientist in oral cancer and saliva diagnostics research. He has authored over 240 peer reviewed scientific publications. He is a fellow of the American Association for the Advancement of Sciences (AAAS), past member of the ADA Council of Scientific Affairs and the past president of American Association of Dental Research (AADR).
  • Department of Oral & Maxillofacial Surgery Claude D. Pepper Center
    Professor and Program Director,CROHA
    President and Chair, Board of Directors ofIADR(International Association for Dental Research)
    Dr. Marc Heft is Professor, Department of Oral & Maxillofacial Surgery and Director, Claude Denson Pepper Center for Research on Oral Health in Aging, University of Florida. He also holds an appointment as Professor, Department of Neuroscience, College of Medicine. He received his B.S. in electrical engineering and D.M.D. from the University of Pennsylvania and his M.A. and Ph.D. in psychology from the American University. After completing a general practice residency at the Baltimore City Hospitals, he was appointed to the National Institute of Dental Research, National Institutes of Health and later to the National Institute on Aging before his appointment to the faculty of the University of Florida. The focus of his research and scholarship has been aging and pain. Dr. Heft is the Immediate-President and Member of the Board of Directors,International Association for Dental Research. He is also Fellow, American Association for the Advancement of Science and Fellow, Gerontological Society of America.
  • West China Hospital, Sichuan University
    Tianjin Medical University General Hospital
    Prof. Qinghua Zhou is a professor of Thoracic Surgery and Molecular Biology of both West China Hospital, Sichuan University and Tianjin Medical University General Hospital. He is the Director of Sichuan Lung Cancer Center/Lung Cancer Institute. He is also the president of Chinese Society of Tumor Metastasis, the past-president of Chinese society of Lung Cancer, and the Director of the MOH National Expert Committee for Lung Cancer Screening, Prevention, Early Diagnosis and Treatment in China. He is also an expert in lung cancer screening, early diagnosis and treatment, served as a member of the International Expert Committee for Lung Cancer Screening and Early Diagnosis, and Molecular Biomarkers in the International Association for Study on Lung Cancer (IASLC). He has been involved over than 40 national and international projects(clinical trials) to study lung cancer screening, early detection and individual treatment through multi- disciplinary National and global collaborations as PI or co-PI. He has successfully administered the several key projects from the State Key Development Program of (for) Basic Research of China, National High Technology Research and Development Program of China, National Tenth-five and Eleven-five Year Key Task Project of China, National Natural Science Foundation of China, collaborated with other researchers in China, and produced over 300 peer-reviewed publications.
  • The University of Texas MD Anderson Cancer Center
    Professor, Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX
    Affiliate Member, Department of Biostatistics, Fred Hutchinson Cancer Research Center, Seattle, WA
    Chief, Section of Early Cancer Detection and Biomarkers, The University of Texas MD Anderson Cancer Center, Houston, TX
    Co-Director, Center for Global Early Cancer Detection, The University of Texas MD Anderson Cancer Center, Houston, TX
    Director, Data Coordinator Center, Center for Global Early Cancer Detection, The University of Texas MD Anderson Cancer Center, Houston, TX
    Research Interests:Cancer early detection (risk assessment, early detection and diagnosis, prognosis);Diagnostic test evaluation;Biomarker evaluation;Group randomized trials.
    Prof. Ziding Feng has extensive experience in biomarker evaluation for cancer risk assessment, early detection, diagnosis, and prognosis. He has been the Principal Investigator of the Data Management Coordinating Center for the Early Detection Research Network since 2000, and has overseen many biomarker validation studies from development to completion. He was the lead biostatistician on a number of EDRN biomarker validation studies that lead to FDA approved cancer biomarkers. As a multi-PI for this project, Prof. Ziding Feng will be responsible for the statistical study design, study coordination, and data analyses aspects of the project. Prof. Ziding Feng is involving in a multi-center saliva biomarker study funded by NIH as the lead biostatistician.
  • Chinese Academy of Medical Science
    Prof. You-lin Qiao is director for Department of Cancer Epidemiology, Cancer Institute/Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College Beijing, China. Before returning back to China in 1997, he was training for 11 years at Johns Hopkins University School of Hygiene and Public Health and Cancer Prevention Studies Branch, NCI/NIH, USA. He is also director of International Collaboration Department, Cancer Foundation of China,and Deputy Director of the National Expert Committee for Cancer Screening and Prevention in China. As an expert in cancer prevention and control, he serves as the WHO Director-General’s Cancer Control Advisory Committee and WHO’s Cancer Technical Advisory Groups for helping to promote cancer prevention and control programs in developing countries. He is involved in many national and international projects to study etiology, primary intervention, and early detection of a variety of cancers through multidisciplinary and global collaborations.
  • Division of Hematology/Oncology, Department of Internal Medicine
    National Cheng Kung University Hospital, Tainan, Taiwan
    Professor Wu-Chou Su is Chief of the Division of Hematology/Oncology in the Department of Internal Medicine at National Cheng Kung University Hospital (NCKUH), Tainan, Taiwan. He is also a Professor and attending Physician within the Department of Internal Medicine at the same institution. He was in charged NCKUH Clinical Trial Center for 6 years and currently he is Director of Cancer Center of NCKUH.After receiving his medical degree from the National Taiwan University College of Medicine, Taipei, Taiwan, Dr. Su completed a residency in internal medicine at National Taiwan University Hospital following military service as an Army Physician. He received a fellowship on the Medical Oncology Training Program at the prestigious Institute of Biomedical Science, Academica Sinica in Taipei. Between 1995 and 1997, Professor Su was a Research Fellow in the Department of Pathology at Yale University School of Medicine, New Haven, Connecticut, USA. He is Board Certified in Internal Medicine, Medical Oncology, Hematology and Hospice Care Medicine.The research interests of Professor Su include the pathogenesis and treatment of lung cancers, the regulation of IL-6/Jak/Stat pathway and its impact on cancer progression, and the development of nanodrugs as novel anti-cancer modalities. Professor Su has published more than a hundred articles and conducted many clinical trials.
  • CEO & Founder, EZlife Bio Inc.
    Start up the company to commercialize EFIRM technology. Lead R&D team to develop EFIRM reader, software, kits and Data system. Lead business development team to build global collaboration network. Lead clinical team to go through regulatory approval of EFIRM products.
  • Floating Hospital for Children Tufts Medical Center
    Dr. Jill Maron is an Associate Professor of Pediatrics at The Floating Hospital for Children at Tufts Medical Center and an Investigator at the Mother Infant Research Institute at Tufts Medical Center. For the past decade, her research has focused on the noninvasive identification of fetal and neonatal transcriptomic biomarkers in noninvasively obtained biofluids. Specifically, her laboratory has been established as a leader in the field of neonatal salivary transcriptomics. She was the first to publish on the enormous amount of global developmental information available through salivary gene expression analyses of premature neonates and has subsequently enhanced mRNA extraction techniques to improve yield, delineated transcriptomic signals in both the cellular and cell-free layers of neonatal saliva, and compared gene expression profiles between neonatal umbilical cord blood and saliva. Her research currently focuses on novel salivary biomarker discovery to better and more safely monitor the health and development of the vulnerable premature newborn.
  • Researcher of Chinese and Western Medicine, professor
    Senior visiting scholar of University of California
    National outstanding contribution expert
    Leader of Shenzhen Institute of Geriatrics
    Director of Shenzhen integrated traditional Chinese and Western medicine center
    vice director of cardiovascular and cerebrovascular diseases of Guangdong Traditional Chinese and Western medicine
    Committee of clinical diagnosis Specialized of China Society of traditional Chinese medicine
  • Austrian Institute of Technology
    Martin Weber has completed his Ph.D. at the age of 29 at the Center for Molecular Biology (ZMBH) in Heidelberg/Germany. He then served in different positions at QIAGEN GmbH (Hilden/Germany) for more than 17 years, heading the corporate research and innovation group in his last position at the company. Since 2012 he is the Head of the Molecular Diagnostics business unit at AIT Austrian Institute of Technology, the biggest non-university research institute in Austria. He has published more than 20 papers and patent applications.
  • Oasis Diagnostics® Corporation
    Dr. Slowey is the Founder and Owner of Oasis Diagnostics® Corporation and its subsidiary Company, Bamburgh Marrsh LLC, founded in 2002, each are pioneers in the area of oral fluid diagnostics and testing. Dr Slowey’sbackground is in Organic Chemistry; after being awarded his Doctorate from the University of Newcastle-upon-Tyne (UK), he spent several years as a Post Doctoral Fellow in Canada then 5 years in the pharmaceutical industry with Sterling Drug [UK]. He has over 32 years of experience in the clinical diagnostic and pharmaceutical industries combined. Over the years he has held positions as Director of International Sales and Chief Operating Officer (COO) and Vice President of Sales and Marketing for companies that were the original pioneers in the development of saliva diagnostic rapid tests for infectious diseases, and oral fluid collection devices. He has extensive experience in structuring strategic alliances and license agreements with both start-up and Fortune 500 companies. Dr Slowey has 30 publications in peer-reviewejournals, fifteen (15) issued patents, twelve (12) filed patent applications and he has made a number of oral presentations at key scientific symposia on a variety of subjects including HIV diagnosis, nucleic acid testing, the status of oral fluid testing, the Japanese Healthcare Business and Thyrotropin Receptor Antibody Assays for the Diagnosis of Graves’ Disease.
  • EUGENOMIC, genomic personalized medicine
    Ana Sabater is the associate Director at EUGENOMIC, genomic personalized medicine. She runs the business strategy and responsible for EUGENOMIC's growth. It is an exciting project that represents the twenty-first century medicine: personalized medicine according to each person's genes. They have developed an innovative and unique methodology for applying pharmacogenetics a unique methodology based on g-Nomic pharmacogenetics interpretation software: g-Nomic: helps the physician to prescribe the right drug at the correct dose for each patient according to his genes. It gives all information related to drug interaction, drug with lifestyle interactions, inhibitions,inductions and calculates dose according to patient's genetics. Ana Sabater constantly giving courses and lectures at the University of Barcelona, in nutrigenetic Masters as well as at national and international congresses related to genomics and pharmacogenetics medicine.